A team of specialists detailed new data and recent breakthroughs in the diagnosis, management and treatment of heart failure with preserved ejection fraction.

Novartis recalled a single lot of valsartan, a blood pressure/heart failure drug the company sells under the brand name Diovan. According to the FDA, this is a Class II recall.

The standard of care for hypertrophic cardiomyopathy has undergone a lot of change in recent years. Many more changes are likely on the way.

An investigational drug therapy from Affinia Therapeutics has secured the FDA's orphan drug designation. This means the company now has access to certain benefits, including tax credits and fee exemptions, as it works toward approval. 

Flu vaccines were also associated with lower rates of all-cause mortality, myocardial infarction and heart failure, researchers noted. 

The registry has collected more than 1.6 million patient records from more than 800 hospitals. "We can do even better," one cardiologist said. "We have to treat heart failure with everything we've got."

A new drug delivery system may help reduce heart failure hospitalizations and related healthcare costs, which are expected to reach $70 billion by 2030.